EXOSENS 62.800 € (-1,95 %)
MICHELIN 31.150 € (-1,05 %)
ESSILORLUXOTTICA 180.600 € (-1,15 %)
HF COMPANY 4.930 € (+9,80 %)
MAGNUM 11.162 € (-0,66 %)
KERING 232.550 € (-1,50 %)
SAINT GOBAIN 76.460 € (-1,14 %)
MERSEN 31.020 € (+9,07 %)
PHILIPS KON 21.920 € (-5,31 %)
ABEO 8.440 € (+2,93 %)
SOITEC 113.100 € (+14,52 %)
HEINEKEN 64.920 € (-2,81 %)
ASM INTERNATIONAL 809.800 € (-0,27 %)
SWI CAPITAL 5.500 € (+2,61 %)
SAFRAN 268.800 € (-0,92 %)
VINCI 126.150 € (-1,87 %)
ALLFUNDS GROUP 8.810 € (+0,06 %)
ING GROEP N.V. 23.880 € (-0,56 %)
CSG 18.448 € (-3,46 %)
LVMH 448.450 € (-1,39 %)
SARTORIUS STED BIO 151.500 € (-3,38 %)
HAL TRUST 169.000 € (-0,82 %)
WITBE 2.300 € (+39,39 %)
VALEO 10.480 € (-0,66 %)
EXAIL TECHNOLOGIES 123.900 € (-0,72 %)
SCHNEIDER ELECTRIC 271.550 € (+0,28 %)
GROUPE SFPI 1.840 € (0,00 %)
AB SCIENCE 1.100 € (-6,62 %)
TELEPERFORMANCE 55.140 € (+1,92 %)
MON COURTIER ENERG 5.700 € (+3,64 %)
ARKEMA 61.350 € (-1,05 %)
VERALLIA 20.180 € (+0,50 %)
Vusion 128.500 € (-1,91 %)
EUROFINS SCIENT. 57.540 € (-3,71 %)
MERCIALYS 12.340 € (-1,75 %)
NN GROUP 73.620 € (-0,22 %)
VALNEVA 2.328 € (-3,56 %)
AHOLD DEL 39.790 € (-2,26 %)
LISI 61.500 € (+2,50 %)
STELLANTIS NV 6.640 € (-0,91 %)
SHELL PLC 37.830 € (-0,33 %)
BE SEMICONDUCTOR 239.400 € (+1,74 %)
DANONE 66.100 € (-1,93 %)
Coca-ColaEuropacif 81.300 € (-2,98 %)
MEDINCELL 24.820 € (+8,57 %)
TOTALENERGIES 78.230 € (-0,05 %)
HEXAOM 35.300 € (-0,56 %)
CAPGEMINI 102.700 € (+3,44 %)
CRCAM NORD CCI 27.730 € (-1,32 %)
AZERION 0.790 € (+2,60 %)
UMG 19.380 € (-0,08 %)
AKZO NOBEL 49.590 € (-1,33 %)
ARCELORMITTAL SA 48.970 € (-0,71 %)
STMICROELECTRONICS 44.720 € (+5,98 %)
DSM FIRMENICH AG 63.360 € (-0,31 %)
L'OREAL 365.600 € (-0,25 %)
E PANGO 0.247 € (+30,34 %)
CRCAM ATL.VEND.CCI 154.000 € (0,00 %)
CRCAM LANGUED CCI 88.500 € (+1,71 %)
AIRBUS 174.620 € (+5,13 %) |
02/04/2026 11:05
Folly Launches First Pill-Strength Hair Health GummyEQS-News: Folly / Key word(s): Product Launch/Private Equity On a Mission to Solve the Supplement Industry's Underdosing & Consistency Crisis 30+ clinically proven ingredients, 16x dosage compared to the average hair gummy; Biotech encapsulation-enabled breakthrough; Results reported in 30 days LONDON, April 2, 2026 /PRNewswire/ -- Folly, the first biotech-powered hair supplement, today announced its global launch alongside a follow-on investment led by Khosla Ventures. The investment will accelerate global commercialization of the breakthrough encapsulation platform and expansion into new wellness categories. Folly delivers 30+ clinically studied ingredients in a gummy form factor, at dosages previously associated only with pills and capsules, using Folly Microspheres, a proprietary microencapsulation system developed by parent company Genecis Bio. It is the first hair supplement to apply drug-delivery science to solve what the company calls "the supplement industry's consistency crisis." Weak Formulas and Poor Consistency Most hair supplements use similar buzzword ingredients: biotin, vitamins, pumpkin seed oil. On paper, many of them look comparable.
Women cycle through products that look promising but either don't deliver meaningful dosing or are too cumbersome to stay on long enough to see results. Folly delivers clinically studied ingredients at meaningful levels, not beauty-level doses designed for marketing appeal. To make this possible in a gummy format, Folly developed a protective microsphere system – Folly Microspheres™ – that helps stabilize sensitive actives during production and digestion. This allows the gummy to maintain higher ingredient loading than typical hair gummies, without compromising taste or daily usability. Luna Yu, Co-Founder and CEO: "Folly was built to solve the supplement industry's delivery crisis: ensuring that clinically studied nutrients actually reach your follicles, not your stomach lining. "I spent years working in pharmaceutical delivery science before realizing the supplement industry had never fully applied these principles. The same approaches that protect active ingredients in drug delivery can protect nutrients in a gummy. That is what Folly Microspheres do." In a 300-person consumer perception study, women who used Folly daily for at least 30 days reported:
Folly launches in April 2026 in the U.S. and U.K., with expansion across Europe and Asia throughout 2026. Visit: www.follynutrition.com / @FollyNutrition
![]() 02.04.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. 2303166 02.04.2026 CET/CEST Source : Webdisclosure.com |
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière
